These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


137 related items for PubMed ID: 17548572

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade.
    Van der Walt A, Butzkueven H, Kolbe S, Marriott M, Alexandrou E, Gresle M, Egan G, Kilpatrick T.
    Pharmacol Ther; 2010 Apr; 126(1):82-93. PubMed ID: 20122960
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.
    Bar-Zohar D, Agosta F, Goldstaub D, Filippi M.
    Mult Scler; 2008 Jul; 14(6):719-27. PubMed ID: 18424478
    [Abstract] [Full Text] [Related]

  • 5. Emerging therapies in multiple sclerosis.
    Farrell R, Heaney D, Giovannoni G.
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):797-816. PubMed ID: 16262563
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Neuroprotection and repair.
    Palace J.
    J Neurol Sci; 2008 Feb 15; 265(1-2):21-5. PubMed ID: 17964604
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status.
    Waxman SG.
    Nat Clin Pract Neurol; 2008 Mar 15; 4(3):159-69. PubMed ID: 18227822
    [Abstract] [Full Text] [Related]

  • 13. Evidence for neuroprotection and remyelination using imaging techniques.
    Arnold DL.
    Neurology; 2007 May 29; 68(22 Suppl 3):S83-90; discussion S91-6. PubMed ID: 17548574
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Experimental models of neuroprotection relevant to multiple sclerosis.
    Yong VW, Giuliani F, Xue M, Bar-Or A, Metz LM.
    Neurology; 2007 May 29; 68(22 Suppl 3):S32-7; discussion S43-54. PubMed ID: 17548566
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Advancement of therapies for neuroprotection in multiple sclerosis.
    Lo A.
    Expert Rev Neurother; 2008 Sep 29; 8(9):1355-66. PubMed ID: 18759548
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The role of neurotrophic factors in the pathology and treatment of multiple sclerosis.
    Mirowska-Guzel D.
    Immunopharmacol Immunotoxicol; 2009 Sep 29; 31(1):32-8. PubMed ID: 18792835
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 7.